Robert Goulart to Mass Screening
This is a "connection" page, showing publications Robert Goulart has written about Mass Screening.
Connection Strength
0.330
-
Nayar R, Chhieng DC, Crothers B, Darragh TM, Davey DD, Eisenhut C, Goulart R, Huang EC, Tabbara SO. Moving forward-the 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors and beyond: implications and suggestions for laboratories. J Am Soc Cytopathol. 2020 Jul - Aug; 9(4):291-303.
Score: 0.119
-
Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FAR, Kinney WK, Massad LS, Mayeaux EJ, Saslow D, Schiffman M, Wentzensen N, Lawson HW, Einstein MH. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol. 2015 Feb; 125(2):330-337.
Score: 0.082
-
Pantanowitz L, Hornish M, Florence R, Goulart R. Vaginal Pap tests status-post hysterectomy. Diagn Cytopathol. 2007 Aug; 35(8):539-40.
Score: 0.049
-
Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, Kinney WK, Massad LS, Mayeaux EJ, Saslow D, Schiffman M, Wentzensen N, Lawson HW, Einstein MH. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015 Feb; 136(2):178-82.
Score: 0.021
-
Nayar R, Goulart RA, Tiscornia-Wasserman PG, Davey DD. Primary human papillomavirus screening for cervical cancer in the United States-US Food and Drug Administration approval, clinical trials, and where we are today. Cancer Cytopathol. 2014 Oct; 122(10):720-9.
Score: 0.020
-
Davey DD, Goulart R, Nayar R. 2013 statement on human papillomavirus DNA test utilization. Am J Clin Pathol. 2014 Apr; 141(4):459-61.
Score: 0.019
-
Davis Davey D, Goulart R, Nayar R. 2013 statement on human papillomavirus [corrected] test utilization. Acta Cytol. 2014; 58(2):113-6.
Score: 0.019